BLUE News and Press, bluebird bio Inc. From 03/25/21

What do playing right field in baseball, deep-sea fishing, and investing in small biotech stocks have in common? Long periods of boredom followed by moments of intense drama. For shareholders of bluebird bio (NASDAQ: BLUE) , Sage Therapeutics (NASDAQ: SAGE) , and...

Orchard Therapeutics is the category leader for engineering and developing hematopoietic stem cell medicines. The company's platform has been validated with 2 approvals in Europe and a diverse pipeline of drug candidates. Hematopoietic stem cells have curative potential for many d...

Genetics is the study of genes, their variations and hereditary characteristics. As Live Science describes it , genetics involves looking at how traits are passed on through generations. So, what is genetics investing? When it comes to genetics investing, companies in this niche...

President Joe Biden is looking to ease travel restrictions around the middle of May, CNBC reports, citing two officials familiar with the matter.The move would relax current restrictions on cross-border travel between the U.S., and Canada and Mexico and inbound international travel from Europ...

bluebird bio (BLUE) has lost ~1.5% in the post-market trading after announcing the departure of its chief medical officer David Davidson with effect from April 16, 2021.However, following the exit, Dr. Davidson will serve as a consultant for six months, supporting the company&#...

GAAP product revenues increased 49%, compared to 2019 driven by Trikafta. GAAP net income increased 130% compared to 2019, largely driven by strong growth in product revenues. Cash fortress stands at $6.7Bn, with a generous capital allocation policy. I reiterate my updated PT ...

Bluebird bio (BLUE) announces new data from the clinical development program for its its elivaldogene autotemcel (eli-cel, Lenti-D) gene therapy in patients with cerebral adrenoleukodystrophy ((CALD)), a rare, X-linked metabolic disorder. Starbeam Study (ALD-102)/Long-Term Follow-Up...

90% of evaluable patients (27/30) alive and free of major functional disabilities (MFDs) at two years follow-up in Phase 2/3 Starbeam study (ALD-102) Patients in long-term follow-up study (LTF-304) continue to remain alive and MFD-free through up to nearly seven years of follo...

Zynteglo pricing excludes a significant part of the patient pool, preventing bluebird from realizing the full potential of the β-thalassemia market. Resumption of Zynteglo marketing is a multiple-step process that includes the conclusion of the internal investigation and a subs...

These Health Care Stocks Are Trending In The Market This Week Health care was one of the most important sectors in the last year. When the pandemic struck, the health care industry was pushed to the limit. With over 118 million people infected and over 2.6 million deaths from the co...